Health technology assessment: a framework.
作者信息
Joore Manuela, Grimm Sabine, Boonen Annelies, de Wit Maarten, Guillemin Francis, Fautrel Bruno
机构信息
KEMTA, Maastricht University Medical Center, Maastricht, Netherlands.
KEMTA, Maastricht University Medical Center, Maastricht, Netherlands
出版信息
RMD Open. 2020 Nov;6(3). doi: 10.1136/rmdopen-2020-001289.
Abstract
摘要
相似文献
1
Health technology assessment: a framework.卫生技术评估：一个框架。
RMD Open. 2020 Nov;6(3). doi: 10.1136/rmdopen-2020-001289.
2
The future impact of science and technology on medicine: basic research.科学技术对医学的未来影响：基础研究
Vital Speeches Day. 1973 Nov 15;40(2):75-80.
3
Diffusion of high technology medical care and cost control--a public policy dilemma.高科技医疗护理的普及与成本控制——一个公共政策困境。
Technol Soc. 1981;3(3):305-22. doi: 10.1016/0160-791x(81)90002-6.
4
How do cardiologists face health economics and health technology assessments?心脏病专家如何面对卫生经济学和卫生技术评估？
Eur Heart J. 2012 Nov;33(22):2757-8.
5
Updating the biomedical engineering curriculum: Inclusion of Health Technology Assessment subjects.更新生物医学工程课程：纳入卫生技术评估科目。
Annu Int Conf IEEE Eng Med Biol Soc. 2010;2010:2967-70. doi: 10.1109/IEMBS.2010.5626160.
6
Health technology assessment in Europe.欧洲的卫生技术评估
Scand J Public Health. 2009 Jun;37(4):335-9. doi: 10.1177/1403494809105860.
7
Medical technology "arms race" adds billions to the nation's bills: the price of health.医疗技术“军备竞赛”使国家账单增加数十亿美元：健康的代价。
N Y Times Web. 1991 Apr 29:A1, B8.
8
Controlling health care costs by controlling technology: a private contractual approach.通过控制技术来控制医疗保健成本：一种私人契约方法。
Yale Law J. 1990 Mar;99(5):1109-26.
9
Transforming mortality: technology and the allocation of resources.改变死亡率：技术与资源分配
South Calif Law Rev. 1991 Nov;65(1):205-24.
10
The ethics and economics of high-technology medicine.高科技医学的伦理与经济学
Contemp Ther. 1983 Dec;9(12):6-16.
引用本文的文献
1
Health technology assessment (HTA) and performance management (PM): a scoping review on the intersecting realms.卫生技术评估（HTA）与绩效管理（PM）：关于交叉领域的范围综述
BMC Health Serv Res. 2025 Jul 3;25(1):917. doi: 10.1186/s12913-025-12879-3.
2
How can actuarial science contribute to the field of health technology assessment? An interdisciplinary perspective.精算学如何为卫生技术评估领域做出贡献？一种跨学科视角。
Int J Technol Assess Health Care. 2025 Jan 6;41(1):e3. doi: 10.1017/S0266462324004781.
3
Behind the scenes of EQA - characteristics, capabilities, benefits and assets of external quality assessment (EQA).EQA的幕后故事——外部质量评估（EQA）的特点、能力、益处及优势
Clin Chem Lab Med. 2025 Jan 6;63(5):898-915. doi: 10.1515/cclm-2024-1293. Print 2025 Apr 28.
4
Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians.评估慢性阻塞性肺疾病干预措施的比较效果：面向临床医生的网状Meta分析教程
Respir Res. 2024 Dec 21;25(1):438. doi: 10.1186/s12931-024-03056-x.
5
A roadmap towards implementing health technology assessment in Oman.实现阿曼卫生技术评估的路线图。
J Health Organ Manag. 2024 Jul 12;38(9):241-257. doi: 10.1108/JHOM-01-2024-0012.
6
Developing and Evaluating Digital Public Health Interventions Using the Digital Public Health Framework DigiPHrame: A Framework Development Study.利用数字公共卫生框架 DigiPHrame 开发和评估数字公共卫生干预措施：框架开发研究。
J Med Internet Res. 2024 Sep 12;26:e54269. doi: 10.2196/54269.
7
Cost-effectiveness analysis of proximal femoral nail versus bipolar hemiarthroplasty for femoral neck fracture.股骨颈骨折股骨近端髓内钉与双极人工股骨头置换术的成本效果分析。
J Orthop Surg Res. 2024 Aug 27;19(1):507. doi: 10.1186/s13018-024-04941-3.
8
Overcoming Barriers in Hospital-Based Health Technology Assessment (HB-HTA): International Expert Panel Consensus.克服医院健康技术评估（HB-HTA）中的障碍：国际专家小组共识
Healthcare (Basel). 2024 Apr 25;12(9):889. doi: 10.3390/healthcare12090889.
9
A health technology assessment of personalized nutrition interventions using the EUnetHTA HTA Core Model.采用欧盟 HTA 核心模型对个性化营养干预措施进行卫生技术评估。
Int J Technol Assess Health Care. 2024 Mar 6;40(1):e15. doi: 10.1017/S0266462324000060.
10
Economic Evaluation of a Personalized Nutrition Plan Based on Omic Sciences Versus a General Nutrition Plan in Adults with Overweight and Obesity: A Modeling Study Based on Trial Data in Denmark.基于组学科学的个性化营养计划与一般营养计划对超重和肥胖成年人的经济评估：一项基于丹麦试验数据的建模研究
Pharmacoecon Open. 2024 Mar;8(2):313-331. doi: 10.1007/s41669-023-00461-8. Epub 2023 Dec 19.
本文引用的文献
1
Health Technology Assessment: Global Advocacy and Local Realities Comment on "Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness".卫生技术评估：全球倡导与本地现实 评“全民健康覆盖的优先事项制定：我们需要基于证据的审议程序，而不仅仅是更多成本效益证据”。
Int J Health Policy Manag. 2017 Apr 1;6(4):233-236. doi: 10.15171/ijhpm.2016.118.
2
Clinical trials provide essential evidence, but rarely offer a vehicle for cost-effectiveness analysis.临床试验提供了重要证据，但很少提供进行成本效益分析的手段。
Value Health. 2015 Mar;18(2):141-2. doi: 10.1016/j.jval.2015.02.005.
3
Mapping of health technology assessment in selected countries.部分国家卫生技术评估情况概述
Int J Technol Assess Health Care. 2013 Oct;29(4):424-34. doi: 10.1017/S0266462313000469.
4
Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.与临床试验同时进行成本效益分析的良好研究实践：药物经济学与结果研究协会随机对照试验-成本效益分析特别工作组报告
Value Health. 2005 Sep-Oct;8(5):521-33. doi: 10.1111/j.1524-4733.2005.00045.x.
Zotero 插件